Completing a special protocol assessment process with the FDA, Alexion Pharmaceuticals Inc. plans to begin a Phase III program of eculizumab for the chronic orphan blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). (BioWorld Today)

While DAC:GLP-1 hit its primary endpoint as a diabetes monotherapy in a Phase II trial that evaluated it in four doses, the drug's nausea and vomiting side effects sent ConjuChem's stock tumbling. (BioWorld Today)

Although Discovery Laboratories Inc. has plenty of financial resources for near-term operations, the Doylestown, Pa.-based company secured a $75 million equity facility that it can access over the next three years. (BioWorld Today)